The Cancer Prevention and Research Institute of Texas awarded Houston-based drugmaker DNAtrix a $10.8 million grant to advance its experimental drug DNX-2401, an oncolytic virus, for treatment of malignant glioma. DNX-2401 selectively attacks tumor cells using a genetically modified adenovirus. The drug, in combination with temozolomide, is being tested against recurrent glioblastoma in a Phase Ib study.

Related Summaries